Sotatercept (Winrevair): The First Drug in Pulmonary Hypertension That Treats the Narrowing, Not the Spasm
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120

Sotatercept (Winrevair): The First Drug in Pulmonary Hypertension That Treats the Narrowing, Not the Spasm

A guide to sotatercept (Winrevair): an activin trap that acts on the growth of the pulmonary vessel wall; in ZENITH, among high-risk patients on background therapy, death, lung transplantation or hospitalisation occurred in 17.4% versus 54.7% on placebo. How it is used and who should see a doctor first.

Sotatercept (Winrevair): The First Drug in Pulmonary Hypertension That Treats the Narrowing, Not the Spasm
Earlier vasodilators relieve the spasm, while sotatercept (Winrevair) is the first drug in pulmonary arterial hypertension to act on the thickening of the vessel wall itself. In high-risk patients it cut the chance of death, lung transplantation or hospitalisation from 54.7% to 17.4%, and the trial was stopped early because of a clear advantage. One injection every three weeks, in addition to background therapy.

Key points

Sotatercept (Winrevair) is a subcutaneous injection given once every three weeks to adults with pulmonary arterial hypertension (PAH), in addition to background therapy. It is the first drug to act not on spasm but on the growth of the vessel wall; it was approved by the FDA in March 2024.

SituationHow it helpsWhat human studies showed
High-risk PAH, on maximum tolerated background therapyfewer deaths, lung transplants or hospitalisations for worseningZENITH (NEJM, 2025), 172 patients: 17.4% versus 54.7% on placebo, hazard ratio 0.24 (95% CI 0.13–0.43; p<0.001) [2]
Hospitalisations (high risk)fewer hospital admissions for worseningZENITH: 9.3% versus 50.0% on placebo [2]
PAH on stable background therapypatients walk further in the six-minute walk testSTELLAR (NEJM, 2023), 323 patients: 40.8 m more than on placebo (95% CI 27.5–54.1; p<0.001); eight of nine secondary endpoints favoured the drug [1]

How it helps

What happens in the pulmonary vessels

Pulmonary arterial hypertension is not high blood pressure in the familiar sense. It concerns the vessels carrying blood from the heart to the lungs.

Cells in the walls of those arteries begin to multiply excessively. The wall thickens, the lumen narrows, resistance to flow rises. The right ventricle must push blood through ever narrower vessels — and gradually wears out.

Clinically this is breathlessness on exertion, fatigue and fainting. The disease is rare, but untreated the outlook is poor.

How it differs from earlier drugs

The three classes on which treatment rested for decades — prostacyclins, endothelin receptor antagonists and phosphodiesterase-5 inhibitors — all essentially do one thing: widen the vessel by relieving spasm.

This works and prolongs life. But the wall keeps thickening regardless of whether the vessel is widened. Figuratively: the pipe furs up from inside while we adjust its bore from outside.

How the trap works

Two opposing signals meet in the cells of the vessel wall:

SignalWhat it doesWhat happens in the disease
Through the BMPR2 receptorRestrains cell divisionWeakened
Through activins and related proteinsDrives divisionAmplified

The balance tips toward growth, and the wall thickens. This is precisely why mutations in the BMPR2 gene are found in a substantial share of patients with the hereditary form.

Sotatercept is built as a fragment of the receptor fused to part of an antibody. It works as a trap: it captures surplus activins from the blood before they reach the cells. The advantage returns to the restraining signal.

Trials

▸ ZENITH (NEJM, 2025) — 172 high-risk patients on the maximum tolerated background therapy. Events were counted rather than metres [2]:

EventSotaterceptPlacebo
Composite (death, lung transplantation or hospitalisation)17.4%54.7%
Death from any cause8.1%15.1%
Lung transplantation1.2%7.0%
Hospitalisation for worsening9.3%50.0%

The trial was stopped early. The interim analysis showed an advantage so clear that continuing to give placebo became unethical.

How it is given

ParameterDetail
RouteSubcutaneous injection
FrequencyOnce every three weeks
Role in the regimenAdded to background therapy
MonitoringHaemoglobin and platelets before every dose during titration
Discuss in advanceFertility

Who should see a doctor first

Side effects

▸ Nosebleeds and telangiectasia — dilated small vessels on the skin and mucous membranes; the most characteristic events.
▸ Rising haemoglobin: the blood thickens more than it should, so levels are monitored regularly.
▸ Falling platelets — the same blood counts cover this.
▸ Effects on fertility: drugs of this class may affect reproductive function, and that conversation belongs before treatment rather than after.

Who it is not for

▸ Patients with pulmonary hypertension of another origin — the mechanism does not address them.
▸ Anyone with an already high haemoglobin or low platelets — decided case by case and requiring monitoring.
▸ Anyone planning pregnancy without discussing the fertility question with their doctor.
▸ As a reason to stop background therapy that is working.

Bottom line

▸ The first mechanism aimed at growth of the vessel wall rather than spasm.
▸ ZENITH: events in 17.4% versus 54.7%; the trial was stopped early for efficacy.
▸ Under regular monitoring — nosebleeds, telangiectasia, rising haemoglobin and falling platelets.

Treatment can be discussed at a consultation; the drug can be ordered here.

References

1. Hoeper MM, et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023;388(16):1478–1490. PMID 36877098

2. Humbert M, et al. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med. 2025;392(20):1987–2000. PMID 40167274

3. WINREVAIR (sotatercept-csrk) — US Prescribing Information, Merck.

Source: Sotatercept (Winrevair): The First Drug in Pulmonary Hypertension That Treats the Narrowing, Not the Spasm — universum.earth. Dr. Pereligyn.

Come back
Request a call back